Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has introduced an anticancer agent Treakisym injection 100mg (generic name: bendamustine hydrochloride) in Japan as a treatment for low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma.
Subscribe to our email newsletter
Treakisym is the first anticancer agent for Eisai to launch in Japan, and although it is already available in the US.
Eisai claims that Treakisym is a novel anticancer agent that exhibits nitrogen mustard-derived alkylating activity and antimetabolic-like activity.
Clinical studies conducted in Japan showed that the agent offers efficacy, has a high response rate, and extends the duration of progression-free survival.
In Japan, SymBio Pharmaceuticals is currently conducting Phase II clinical studies with the agent in relapsed and refractory intermediate- and high-grade B-cell non-Hodgkin’s lymphoma and untreated multiple myeloma as part of an indication expansion program.
Following the debut of its first anticancer agent Treakisym, Eisai plans to continue to expand its portfolio of oncology products with agents such as eribulin (generic name), for the treatment of breast cancer.